The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
TCT 2021 | Long-term follow-up of a “fast-DC” immunotherapy as a post-remission strategy for AML
Yngvar Floisand, MD, PhD, Oslo University Hospital, Oslo, Norway, discusses the long-term follow-up results of dendritic cell (DC) immunotherapy targeting PRAME and WT-1 as a post-remission strategy in patients with acute myeloid leukemia (AML). The findings suggest that immunotherapy with autologous DC transfected with PRAME and WT-1 RNA is safe and feasible, whilst demonstrating encouraging long-term progression-free survival and overall survival. This interview took place during the Transplantation & Cellular Therapy (TCT) 2021 Meetings.
